Key result
Pharmacological treatments and drug-eluting stents for the prevention of restenosis following percutaneous coronary interventions are critically reviewed across various stages of development.
Why the study?
What is the current status of pharmacological treatments for the prevention of restenosis following percutaneous coronary interventions?
Population
Patients undergoing percutaneous coronary interventions (PCI) and preclinical animal models of restenosis
Design
Review
Authors
Loading...
Systemic pharmacotherapy remains largely ineffective post-PCI; leaves open targeted local delivery and novel antiproliferative agents in development.
What is the current status of pharmacological treatments for the prevention of restenosis following percutaneous coronary interventions?
This review highlights the shift from largely unsuccessful systemic pharmacological therapies to promising local drug delivery systems like drug-eluting stents for preventing restenosis after PCI.
Linde et al. (2001) conducted a review in Coronary artery disease and restenosis. Pharmacological treatments and drug-eluting stents was evaluated. Pharmacological treatments and drug-eluting stents for the prevention of restenosis following percutaneous coronary interventions are critically reviewed across various stages of development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: